Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
The Pediatric Artificial Pancreas (PEDAP) Trial of Control-IQ Technology in Young Children in Type 1 Diabetes
The purpose of this study is to learn whether an investigational automated insulin delivery system ("study system") for young children (2 yo to less than 6 yo) with type 1 diabetes can safely improve blood glucose (sometimes called blood sugar) control.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Tandem t:slim X2 with Control-IQ Technology Pro
- device: Tandem t:slim X2 with Control-IQ Technology V1.5
- device: Standard Care (SC)
Eligibility
Inclusion Criteria:
1. Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least
6 months and using insulin for at least 6 months
2. Familiarity and use of a carbohydrate ratio for meal boluses.
3. Age ≥2 and <6 years old
4. Living with one or more parent/legal guardian knowledgeable about emergency procedures
for severe hypoglycemia and able to contact emergency services and study staff.
5. Investigator has confidence that the parent can successfully operate all study devices
and is capable of adhering to the protocol
6. Willingness to switch to lispro (Humalog) or aspart (Novolog) if not using already,
and to use no other insulin besides lispro (Humalog) or aspart (Novolog) during the
study for participants using a study-provided Tandem pump during the study.
• Study will not be providing insulin; therefore, participants will need to have
access to either lispro or aspart
7. Total daily insulin dose (TDD) at least 5 U/day
8. Body weight at least 20 lbs.
9. Willingness not to start any new non-insulin glucose-lowering agent during the course
of the trial (see section 2.3)
10. Participant and parent(s)/guardian(s) willingness to participate in all training
sessions as directed by study staff.
11. Parent/guardian proficient in reading and writing English.
Exclusion Criteria:
1. Concurrent use of any non-insulin glucose-lowering agent (including Glucagon-like
peptide-1 [GLP-1] agonists, Symlin, Dipeptidyl peptidase-4 [DPP-4] inhibitors,
Sodium-glucose Cotransporter-2 (SGLT-2) inhibitors, sulfonylureas).
2. Hemophilia or any other bleeding disorder
3. History of >1 severe hypoglycemic event with seizure or loss of consciousness in the
last 3 months
4. History of >1 DKA event in the last 6 months not related to illness, infusion set
failure, or initial diagnosis
5. History of chronic renal disease or currently on hemodialysis
6. History of adrenal insufficiency
7. Hypothyroidism that is not adequately treated
8. Use of oral or injectable steroids within the last 8 weeks
9. Known, ongoing adhesive intolerance
10. Plans to receive blood transfusions or erythropoietin injections during the course of
the study
11. A condition, which in the opinion of the investigator or designee, would put the
participant or study at risk (specified in the study procedure manual)
12. Currently using any closed-loop system, or using an insulin pump that is incompatible
with use of the study CGM
13. Participation in another pharmaceutical or device trial at the time of enrollment or
during the study
14. Employed by, or having immediate family members employed by Tandem Diabetes Care,
Inc., or having a direct supervisor at place of employment who is also directly
involved in conducting the clinical trial (as a study investigator, coordinator,
etc.); or having a first-degree relative who is directly involved in conducting the
clinical trial
Ages Eligible for Study
24 Months - 71 Months
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Ryan Kingman
650-736-4417
I'm interested
Psoriasis Clinical Trials
The Pediatric Artificial Pancreas (PEDAP) Trial of Control-IQ Technology in Young Children in Type 1 Diabetes
The purpose of this study is to learn whether an investigational automated insulin delivery system ("study system") for young children (2 yo to less than 6 yo) with type 1 diabetes can safely improve blood glucose (sometimes called blood sugar) control.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Tandem t:slim X2 with Control-IQ Technology Pro
- device: Tandem t:slim X2 with Control-IQ Technology V1.5
- device: Standard Care (SC)
Eligibility
Inclusion Criteria:
1. Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least
6 months and using insulin for at least 6 months
2. Familiarity and use of a carbohydrate ratio for meal boluses.
3. Age ≥2 and <6 years old
4. Living with one or more parent/legal guardian knowledgeable about emergency procedures
for severe hypoglycemia and able to contact emergency services and study staff.
5. Investigator has confidence that the parent can successfully operate all study devices
and is capable of adhering to the protocol
6. Willingness to switch to lispro (Humalog) or aspart (Novolog) if not using already,
and to use no other insulin besides lispro (Humalog) or aspart (Novolog) during the
study for participants using a study-provided Tandem pump during the study.
• Study will not be providing insulin; therefore, participants will need to have
access to either lispro or aspart
7. Total daily insulin dose (TDD) at least 5 U/day
8. Body weight at least 20 lbs.
9. Willingness not to start any new non-insulin glucose-lowering agent during the course
of the trial (see section 2.3)
10. Participant and parent(s)/guardian(s) willingness to participate in all training
sessions as directed by study staff.
11. Parent/guardian proficient in reading and writing English.
Exclusion Criteria:
1. Concurrent use of any non-insulin glucose-lowering agent (including Glucagon-like
peptide-1 [GLP-1] agonists, Symlin, Dipeptidyl peptidase-4 [DPP-4] inhibitors,
Sodium-glucose Cotransporter-2 (SGLT-2) inhibitors, sulfonylureas).
2. Hemophilia or any other bleeding disorder
3. History of >1 severe hypoglycemic event with seizure or loss of consciousness in the
last 3 months
4. History of >1 DKA event in the last 6 months not related to illness, infusion set
failure, or initial diagnosis
5. History of chronic renal disease or currently on hemodialysis
6. History of adrenal insufficiency
7. Hypothyroidism that is not adequately treated
8. Use of oral or injectable steroids within the last 8 weeks
9. Known, ongoing adhesive intolerance
10. Plans to receive blood transfusions or erythropoietin injections during the course of
the study
11. A condition, which in the opinion of the investigator or designee, would put the
participant or study at risk (specified in the study procedure manual)
12. Currently using any closed-loop system, or using an insulin pump that is incompatible
with use of the study CGM
13. Participation in another pharmaceutical or device trial at the time of enrollment or
during the study
14. Employed by, or having immediate family members employed by Tandem Diabetes Care,
Inc., or having a direct supervisor at place of employment who is also directly
involved in conducting the clinical trial (as a study investigator, coordinator,
etc.); or having a first-degree relative who is directly involved in conducting the
clinical trial
Ages Eligible for Study
24 Months - 71 Months
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Ryan Kingman
650-736-4417
I'm interested
Dermatology Clinical Trials
The Pediatric Artificial Pancreas (PEDAP) Trial of Control-IQ Technology in Young Children in Type 1 Diabetes
The purpose of this study is to learn whether an investigational automated insulin delivery system ("study system") for young children (2 yo to less than 6 yo) with type 1 diabetes can safely improve blood glucose (sometimes called blood sugar) control.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Tandem t:slim X2 with Control-IQ Technology Pro
- device: Tandem t:slim X2 with Control-IQ Technology V1.5
- device: Standard Care (SC)
Eligibility
Inclusion Criteria:
1. Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least
6 months and using insulin for at least 6 months
2. Familiarity and use of a carbohydrate ratio for meal boluses.
3. Age ≥2 and <6 years old
4. Living with one or more parent/legal guardian knowledgeable about emergency procedures
for severe hypoglycemia and able to contact emergency services and study staff.
5. Investigator has confidence that the parent can successfully operate all study devices
and is capable of adhering to the protocol
6. Willingness to switch to lispro (Humalog) or aspart (Novolog) if not using already,
and to use no other insulin besides lispro (Humalog) or aspart (Novolog) during the
study for participants using a study-provided Tandem pump during the study.
• Study will not be providing insulin; therefore, participants will need to have
access to either lispro or aspart
7. Total daily insulin dose (TDD) at least 5 U/day
8. Body weight at least 20 lbs.
9. Willingness not to start any new non-insulin glucose-lowering agent during the course
of the trial (see section 2.3)
10. Participant and parent(s)/guardian(s) willingness to participate in all training
sessions as directed by study staff.
11. Parent/guardian proficient in reading and writing English.
Exclusion Criteria:
1. Concurrent use of any non-insulin glucose-lowering agent (including Glucagon-like
peptide-1 [GLP-1] agonists, Symlin, Dipeptidyl peptidase-4 [DPP-4] inhibitors,
Sodium-glucose Cotransporter-2 (SGLT-2) inhibitors, sulfonylureas).
2. Hemophilia or any other bleeding disorder
3. History of >1 severe hypoglycemic event with seizure or loss of consciousness in the
last 3 months
4. History of >1 DKA event in the last 6 months not related to illness, infusion set
failure, or initial diagnosis
5. History of chronic renal disease or currently on hemodialysis
6. History of adrenal insufficiency
7. Hypothyroidism that is not adequately treated
8. Use of oral or injectable steroids within the last 8 weeks
9. Known, ongoing adhesive intolerance
10. Plans to receive blood transfusions or erythropoietin injections during the course of
the study
11. A condition, which in the opinion of the investigator or designee, would put the
participant or study at risk (specified in the study procedure manual)
12. Currently using any closed-loop system, or using an insulin pump that is incompatible
with use of the study CGM
13. Participation in another pharmaceutical or device trial at the time of enrollment or
during the study
14. Employed by, or having immediate family members employed by Tandem Diabetes Care,
Inc., or having a direct supervisor at place of employment who is also directly
involved in conducting the clinical trial (as a study investigator, coordinator,
etc.); or having a first-degree relative who is directly involved in conducting the
clinical trial
Ages Eligible for Study
24 Months - 71 Months
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Ryan Kingman
650-736-4417
I'm interested
Pediatric Dermatology Clinical Trials
The Pediatric Artificial Pancreas (PEDAP) Trial of Control-IQ Technology in Young Children in Type 1 Diabetes
The purpose of this study is to learn whether an investigational automated insulin delivery system ("study system") for young children (2 yo to less than 6 yo) with type 1 diabetes can safely improve blood glucose (sometimes called blood sugar) control.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Tandem t:slim X2 with Control-IQ Technology Pro
- device: Tandem t:slim X2 with Control-IQ Technology V1.5
- device: Standard Care (SC)
Eligibility
Inclusion Criteria:
1. Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least
6 months and using insulin for at least 6 months
2. Familiarity and use of a carbohydrate ratio for meal boluses.
3. Age ≥2 and <6 years old
4. Living with one or more parent/legal guardian knowledgeable about emergency procedures
for severe hypoglycemia and able to contact emergency services and study staff.
5. Investigator has confidence that the parent can successfully operate all study devices
and is capable of adhering to the protocol
6. Willingness to switch to lispro (Humalog) or aspart (Novolog) if not using already,
and to use no other insulin besides lispro (Humalog) or aspart (Novolog) during the
study for participants using a study-provided Tandem pump during the study.
• Study will not be providing insulin; therefore, participants will need to have
access to either lispro or aspart
7. Total daily insulin dose (TDD) at least 5 U/day
8. Body weight at least 20 lbs.
9. Willingness not to start any new non-insulin glucose-lowering agent during the course
of the trial (see section 2.3)
10. Participant and parent(s)/guardian(s) willingness to participate in all training
sessions as directed by study staff.
11. Parent/guardian proficient in reading and writing English.
Exclusion Criteria:
1. Concurrent use of any non-insulin glucose-lowering agent (including Glucagon-like
peptide-1 [GLP-1] agonists, Symlin, Dipeptidyl peptidase-4 [DPP-4] inhibitors,
Sodium-glucose Cotransporter-2 (SGLT-2) inhibitors, sulfonylureas).
2. Hemophilia or any other bleeding disorder
3. History of >1 severe hypoglycemic event with seizure or loss of consciousness in the
last 3 months
4. History of >1 DKA event in the last 6 months not related to illness, infusion set
failure, or initial diagnosis
5. History of chronic renal disease or currently on hemodialysis
6. History of adrenal insufficiency
7. Hypothyroidism that is not adequately treated
8. Use of oral or injectable steroids within the last 8 weeks
9. Known, ongoing adhesive intolerance
10. Plans to receive blood transfusions or erythropoietin injections during the course of
the study
11. A condition, which in the opinion of the investigator or designee, would put the
participant or study at risk (specified in the study procedure manual)
12. Currently using any closed-loop system, or using an insulin pump that is incompatible
with use of the study CGM
13. Participation in another pharmaceutical or device trial at the time of enrollment or
during the study
14. Employed by, or having immediate family members employed by Tandem Diabetes Care,
Inc., or having a direct supervisor at place of employment who is also directly
involved in conducting the clinical trial (as a study investigator, coordinator,
etc.); or having a first-degree relative who is directly involved in conducting the
clinical trial
Ages Eligible for Study
24 Months - 71 Months
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Ryan Kingman
650-736-4417
I'm interested
The Pediatric Artificial Pancreas (PEDAP) Trial of Control-IQ Technology in Young Children in Type 1 Diabetes
The purpose of this study is to learn whether an investigational automated insulin delivery system ("study system") for young children (2 yo to less than 6 yo) with type 1 diabetes can safely improve blood glucose (sometimes called blood sugar) control.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Tandem t:slim X2 with Control-IQ Technology Pro
- device: Tandem t:slim X2 with Control-IQ Technology V1.5
- device: Standard Care (SC)
Eligibility
Inclusion Criteria:
1. Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least
6 months and using insulin for at least 6 months
2. Familiarity and use of a carbohydrate ratio for meal boluses.
3. Age ≥2 and <6 years old
4. Living with one or more parent/legal guardian knowledgeable about emergency procedures
for severe hypoglycemia and able to contact emergency services and study staff.
5. Investigator has confidence that the parent can successfully operate all study devices
and is capable of adhering to the protocol
6. Willingness to switch to lispro (Humalog) or aspart (Novolog) if not using already,
and to use no other insulin besides lispro (Humalog) or aspart (Novolog) during the
study for participants using a study-provided Tandem pump during the study.
• Study will not be providing insulin; therefore, participants will need to have
access to either lispro or aspart
7. Total daily insulin dose (TDD) at least 5 U/day
8. Body weight at least 20 lbs.
9. Willingness not to start any new non-insulin glucose-lowering agent during the course
of the trial (see section 2.3)
10. Participant and parent(s)/guardian(s) willingness to participate in all training
sessions as directed by study staff.
11. Parent/guardian proficient in reading and writing English.
Exclusion Criteria:
1. Concurrent use of any non-insulin glucose-lowering agent (including Glucagon-like
peptide-1 [GLP-1] agonists, Symlin, Dipeptidyl peptidase-4 [DPP-4] inhibitors,
Sodium-glucose Cotransporter-2 (SGLT-2) inhibitors, sulfonylureas).
2. Hemophilia or any other bleeding disorder
3. History of >1 severe hypoglycemic event with seizure or loss of consciousness in the
last 3 months
4. History of >1 DKA event in the last 6 months not related to illness, infusion set
failure, or initial diagnosis
5. History of chronic renal disease or currently on hemodialysis
6. History of adrenal insufficiency
7. Hypothyroidism that is not adequately treated
8. Use of oral or injectable steroids within the last 8 weeks
9. Known, ongoing adhesive intolerance
10. Plans to receive blood transfusions or erythropoietin injections during the course of
the study
11. A condition, which in the opinion of the investigator or designee, would put the
participant or study at risk (specified in the study procedure manual)
12. Currently using any closed-loop system, or using an insulin pump that is incompatible
with use of the study CGM
13. Participation in another pharmaceutical or device trial at the time of enrollment or
during the study
14. Employed by, or having immediate family members employed by Tandem Diabetes Care,
Inc., or having a direct supervisor at place of employment who is also directly
involved in conducting the clinical trial (as a study investigator, coordinator,
etc.); or having a first-degree relative who is directly involved in conducting the
clinical trial
Ages Eligible for Study
24 Months - 71 Months
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Ryan Kingman
650-736-4417
I'm interested
The Pediatric Artificial Pancreas (PEDAP) Trial of Control-IQ Technology in Young Children in Type 1 Diabetes
The purpose of this study is to learn whether an investigational automated insulin delivery system ("study system") for young children (2 yo to less than 6 yo) with type 1 diabetes can safely improve blood glucose (sometimes called blood sugar) control.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: Tandem t:slim X2 with Control-IQ Technology Pro
- device: Tandem t:slim X2 with Control-IQ Technology V1.5
- device: Standard Care (SC)
Eligibility
Inclusion Criteria:
1. Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least
6 months and using insulin for at least 6 months
2. Familiarity and use of a carbohydrate ratio for meal boluses.
3. Age ≥2 and <6 years old
4. Living with one or more parent/legal guardian knowledgeable about emergency procedures
for severe hypoglycemia and able to contact emergency services and study staff.
5. Investigator has confidence that the parent can successfully operate all study devices
and is capable of adhering to the protocol
6. Willingness to switch to lispro (Humalog) or aspart (Novolog) if not using already,
and to use no other insulin besides lispro (Humalog) or aspart (Novolog) during the
study for participants using a study-provided Tandem pump during the study.
• Study will not be providing insulin; therefore, participants will need to have
access to either lispro or aspart
7. Total daily insulin dose (TDD) at least 5 U/day
8. Body weight at least 20 lbs.
9. Willingness not to start any new non-insulin glucose-lowering agent during the course
of the trial (see section 2.3)
10. Participant and parent(s)/guardian(s) willingness to participate in all training
sessions as directed by study staff.
11. Parent/guardian proficient in reading and writing English.
Exclusion Criteria:
1. Concurrent use of any non-insulin glucose-lowering agent (including Glucagon-like
peptide-1 [GLP-1] agonists, Symlin, Dipeptidyl peptidase-4 [DPP-4] inhibitors,
Sodium-glucose Cotransporter-2 (SGLT-2) inhibitors, sulfonylureas).
2. Hemophilia or any other bleeding disorder
3. History of >1 severe hypoglycemic event with seizure or loss of consciousness in the
last 3 months
4. History of >1 DKA event in the last 6 months not related to illness, infusion set
failure, or initial diagnosis
5. History of chronic renal disease or currently on hemodialysis
6. History of adrenal insufficiency
7. Hypothyroidism that is not adequately treated
8. Use of oral or injectable steroids within the last 8 weeks
9. Known, ongoing adhesive intolerance
10. Plans to receive blood transfusions or erythropoietin injections during the course of
the study
11. A condition, which in the opinion of the investigator or designee, would put the
participant or study at risk (specified in the study procedure manual)
12. Currently using any closed-loop system, or using an insulin pump that is incompatible
with use of the study CGM
13. Participation in another pharmaceutical or device trial at the time of enrollment or
during the study
14. Employed by, or having immediate family members employed by Tandem Diabetes Care,
Inc., or having a direct supervisor at place of employment who is also directly
involved in conducting the clinical trial (as a study investigator, coordinator,
etc.); or having a first-degree relative who is directly involved in conducting the
clinical trial
Ages Eligible for Study
24 Months - 71 Months
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Ryan Kingman
650-736-4417
I'm interested